Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.83 |
| ▸ | FAP | Q12884 | 6/20 | 0.71 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.71 |
| ▸ | GHSR | Q92847 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639988 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL14935777 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637493 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3969508 | 0.94 | DPP4 (0.80) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL638362 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637386 | 0.94 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL16391894 | 0.94 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637743 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3548101 | 0.93 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL636842 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004897-A | Method for preparing linagliptin | 杭州新曦科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-120004897-A | Method for preparing linagliptin | 杭州新曦科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120004897-A | Method for preparing linagliptin | 杭州新曦科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11401269-B2 | Intermediates and processes for the preparation of Linagliptin and its salts | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2022-08-02 | — | — | US | disclosed |
| CN-114527200-A | Method for detecting related substances of linagliptin | 成都倍特药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3794001-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF LINAGLIPTIN AND ITS SALTS | CAMBREX PROFARMACO MILANO S R L (IT) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401269-B2 | Intermediates and processes for the preparation of Linagliptin and its salts | DPP4, DPP8, DPP9 | DPP4 1/4885FAP 95/4885POU2F2 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.